Skip to main content
Equibles

BARCLAYS PLC

Position in SLS — SELLAS Life Sciences Group, Inc.

CIK 312069 LONDON, X0
Back to SLS Full portfolio

Position in SLS

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$528,156
+$391,054 QoQ
Shares Held
35,783
+10.4% QoQ
Ownership
0.018%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#87
of 192 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in SLS Over Time

Shares Held

Position Value (USD)

Derivatives in SLS

reported options exposure · as of Jun 30, 2026
CallValue
$0
CallShares
0
PutValue
$11,831,616
PutShares
801,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

BARCLAYS PLC holds $1,710,275,600 across 455 Biotechnology names. SLS ranks #161 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 733,274 $364,239,192
2 REGN
Regeneron Pharmaceuticals, Inc.
 256,192 $159,745,957
3 IONS
Ionis Pharmaceuticals Inc
 1,603,136 $127,112,653
4 ARGX
Argenx SE
 134,427 $124,717,337
5 MRNA
Moderna, Inc.
 1,035,126 $72,489,872
6 BBIO
BridgeBio Pharma, Inc.
 714,423 $53,210,224
7 TGTX
Tg Therapeutics, Inc.
 957,848 $52,624,168
8 DNTH
Dianthus Therapeutics, Inc. /DE/
 431,753 $42,087,281

All Filings in SLS

Export CSV
7 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $528,156 35,783
2026-06-30 $11,831,616 801,600
2026-03-31 $137,102 32,412
2025-12-31 $1,926,597 511,034
2025-12-31 $754,000 200,000
2025-09-30 $294,114 182,680
2025-06-30 $378,438 172,803